1
|
Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses. MEDICINES 2021; 8:medicines8100056. [PMID: 34677485 PMCID: PMC8538131 DOI: 10.3390/medicines8100056] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 09/12/2021] [Accepted: 09/16/2021] [Indexed: 01/15/2023]
Abstract
Background: Very few studies of the antiviral potential of lignosulfonates have been published. With the aim of oral application, among various groups of natural products, the relative antiviral potency of lignosulfonate and its ability to rapidly inactivate viruses were investigated. Methods: As target cells, MT-4 cells in suspension and attached Vero cells were used for infections with human immunodeficiency virus (HIV) and human herpes simplex type-1 virus (HSV). Mock- or virus-infected cells were incubated for 3–5 days with various concentrations of test samples, and the viable cell number was determined with the MTT method. For the shorter exposure experiments, higher titers of HIV or HSV were exposed to test samples for 10 or 3 min, diluted to a normal multiplicity of infection (MOI), and applied to the cells. Antiviral activity was quantified by using the chemotherapy index. Results: In the long-exposure system, lignosulfonates showed comparable anti-HIV activity with those of AZT, ddC, and sulfated polysaccharides, and it exceeded those of hundreds of tannins and flavonoids. When the exposure time was shortened, the chemotherapeutic index of the lignosulfonates for HIV was increased 27-fold. At a physiological pH, lignosulfonate showed higher anti-HIV activity than commercial alkali-lignin, dealkali-lignin, and humic acid, possibly due to the higher solubility and purity. Conclusions: With their rapid virus-inactivation capabilities, lignosulfonates may be useful for the prevention or treatment of virally induced oral diseases.
Collapse
|
2
|
Niculescu AG, Grumezescu AM. Natural Compounds for Preventing Ear, Nose, and Throat-Related Oral Infections. PLANTS 2021; 10:plants10091847. [PMID: 34579380 PMCID: PMC8468404 DOI: 10.3390/plants10091847] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 09/01/2021] [Accepted: 09/03/2021] [Indexed: 12/18/2022]
Abstract
Oral health is an essential element in maintaining general well-being. By preserving the complex equilibrium within the oral microbial community, commensal microorganisms can protect against extrinsic pathogenic threats. However, when an imbalance occurs, the organism is susceptible to a broad range of infections. Synthetic drugs can be administered to help the body fight against the fungal, bacterial, or viral burden. Nonetheless, they may produce undesirable consequences such as toxicity, adverse effects, and drug resistance. In this respect, research has focused on finding safer and more efficient alternatives. Particularly, increasing attention has been drawn towards developing novel formulations based on natural compounds. This paper reviews the plant-based, algae-based, and beehive products investigated for their antimicrobial properties, aiming to thoroughly present the state of the art on oral infection prevention in the ear, nose, and throat (ENT) field.
Collapse
Affiliation(s)
- Adelina-Gabriela Niculescu
- Faculty of Engineering in Foreign Languages, University Politehnica of Bucharest, 060042 Bucharest, Romania;
- Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, 060042 Bucharest, Romania
| | - Alexandru Mihai Grumezescu
- Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, 060042 Bucharest, Romania
- Research Institute of the University of Bucharest—ICUB, University of Bucharest, 050657 Bucharest, Romania
- Academy of Romanian Scientists, 3 Ilfov Street, 50044 Bucharest, Romania
- Correspondence: ; Tel.: +40-21-402-3997
| |
Collapse
|
3
|
Sakagami H, Furukawa T, Satoh K, Amano S, Iijima Y, Koshikawa T, Asai D, Fukuchi K, Takemura H, Kanamoto T, Yokose S. Re-Evaluation of Chemotherapeutic Potential of Pyoktanin Blue. MEDICINES (BASEL, SWITZERLAND) 2021; 8:medicines8070033. [PMID: 34206186 PMCID: PMC8305689 DOI: 10.3390/medicines8070033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/04/2021] [Accepted: 06/15/2021] [Indexed: 06/13/2023]
Abstract
Background: Pyoktanin blue (PB) is used for staining tissues and cells, and it is applied in photodynamic therapy due to its potent bactericidal activity. However, clinical application of PB as an antiviral and antitumor agent has been limited due to its potent toxicity. For clinical application, the antitumor and antiviral activity as well as the neurotoxicity of PB were re-evaluated with a chemotherapeutic index. Methods: Tumor-specificity (TS) was determined by the ratio of CC50 against normal oral cells/oral squamous cell carcinoma (OSCC); neurotoxicity by that of normal oral/neuronal cells; antiviral activity by that of mock-infected/virus-infected cells; and potency-selectivity expression (PSE) by dividing TS by CC50 (OSCC). Results: Antitumor activity of PB (assessed by TS and PSE) was comparable with that of DXR and much higher than that of 5-FU and melphalan. PB induced caspase-3 activation and subG1 cell accumulation in an OSCC cell line (Ca9-22). PB and anticancer drugs showed comparable cytotoxicity against both neuronal cells and OSCC cell lines. PB showed no detectable anti-HIV/HSV activity, in contrast to reverse transferase inhibitors, sulfated glucans, and alkaline extract of leaves of S.P. Conclusions: PB showed first-class anticancer activity and neurotoxicity, suggesting the importance of establishing the safe treatment schedule.
Collapse
Affiliation(s)
- Hiroshi Sakagami
- Research Institute of Odontology (M-RIO), Meikai University, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan;
| | - Toshiko Furukawa
- Division of Endodontics and Operative Dentistry, School of Dentistry, Meikai University, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan; (T.F.); (S.Y.)
| | - Keitaro Satoh
- Division of Pharmacology, Meikai University School of Dentistry, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan;
| | - Shigeru Amano
- Research Institute of Odontology (M-RIO), Meikai University, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan;
| | - Yosuke Iijima
- Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama 350-8550, Japan;
| | - Takuro Koshikawa
- Department of Microbiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Japan; (T.K.); (D.A.); (H.T.)
| | - Daisuke Asai
- Department of Microbiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Japan; (T.K.); (D.A.); (H.T.)
- Laboratory of Microbiology, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan;
| | - Kunihiko Fukuchi
- Graduate School of Health Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan;
| | - Hiromu Takemura
- Department of Microbiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Japan; (T.K.); (D.A.); (H.T.)
| | - Taisei Kanamoto
- Laboratory of Microbiology, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan;
| | - Satoshi Yokose
- Division of Endodontics and Operative Dentistry, School of Dentistry, Meikai University, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan; (T.F.); (S.Y.)
| |
Collapse
|
4
|
Sakagami H, Nakatani S, Enomoto A, Ota S, Kaneko M, Sugimoto M, Horiuchi M, Toeda K, Oizumi T. Multi-Omics Analysis of Anti-Inflammatory Action of Alkaline Extract of the Leaves of Sasa sp. J Clin Med 2021; 10:jcm10102100. [PMID: 34068182 PMCID: PMC8152990 DOI: 10.3390/jcm10102100] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 04/29/2021] [Accepted: 05/11/2021] [Indexed: 02/07/2023] Open
Abstract
Efficient utilization of alkaline extracts of several plants for the treatment of oral diseases has been reported. To investigate the mechanism of anti-inflammatory activity of alkaline extract of the leaves of Sasa sp. (SE), multi-omics analysis using metabolomics and DNA array was performed. Human gingival fibroblasts (HGFs) were treated for IL-1β to induce inflammation (detected by PGE2 production in culture medium) in the presence or absence of SE. Both IL-1β and SE showed slight hormetic growth stimulation against HGF. SE inhibited PGE2 production dose- and time-dependently. Its inhibitory action was more pronounced by first treating the cells with SE, rather than with IL-1β. At 3 h after IL-1β treatment, 18 amino acids (except cysteine and glutamic acid), total glutathione (GSH, GSSG, Cys-GSH disulfide), Met-sulfoxide, 5-oxoproline, and SAM declined, whereas DNA expressions of AKT, CASP3, and CXCL3 were elevated. These changes were reversed by simultaneous treatment with SE. The present study suggests that the anti-inflammatory action of SE is mediated via various metabolic pathways for cell survival, apoptosis, and leukocyte recruitment.
Collapse
Affiliation(s)
- Hiroshi Sakagami
- Meikai University Research Institute of Odontology (M-RIO), Meikai University School of Dentistry, 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan
- Correspondence: ; Tel.: +81-049-279-2758
| | - Sachie Nakatani
- Graduate School of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan;
| | - Ayame Enomoto
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan; (A.E.); (S.O.); (M.K.); (M.S.)
| | - Sana Ota
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan; (A.E.); (S.O.); (M.K.); (M.S.)
| | - Miku Kaneko
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan; (A.E.); (S.O.); (M.K.); (M.S.)
| | - Masahiro Sugimoto
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan; (A.E.); (S.O.); (M.K.); (M.S.)
- Research and Development Center for Minimally Invasive Therapies, Institute of Medical Science, Tokyo Medical University, Shinjuku, Tokyo 160-0022, Japan
| | - Misaki Horiuchi
- Daiwa Biological Research Institute Co., Ltd., Sakado 3-2-1, Takatsu-ku, Kawasaki, Kanagawa 213-0012, Japan; (M.H.); (K.T.); (T.O.)
| | - Kazuki Toeda
- Daiwa Biological Research Institute Co., Ltd., Sakado 3-2-1, Takatsu-ku, Kawasaki, Kanagawa 213-0012, Japan; (M.H.); (K.T.); (T.O.)
| | - Takaaki Oizumi
- Daiwa Biological Research Institute Co., Ltd., Sakado 3-2-1, Takatsu-ku, Kawasaki, Kanagawa 213-0012, Japan; (M.H.); (K.T.); (T.O.)
| |
Collapse
|